In what may be a breakthrough for India in vaccine production and development of monoclonal antibodies (MABS) against the Nipah virus, the Institute of Advanced Virology (IAV) in Kerala has developed non-infectious Nipah virus-like particles (VLPs).
This will also help in testing the effectiveness of preventing the entry of Nipah in target cells. This is a major development as India used to import antibodies.
During the 2018 outbreak, a non-patented drug developed by Christopher C Broder from Australia was imported for compassionate use from the University of Queensland.
Last year, Business Standard had reported that the Indian Council of Medical Research (ICMR) is in talks with the Serum Institute of India (SII) for local manufacturing of MABS. The MABS are used on compassionate grounds for treating Nipah virus infections. However, it did not take off, as the volume was much less in India.
Esta historia es de la edición June 04, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor ? Conectar
Esta historia es de la edición June 04, 2024 de Business Standard.
Comience su prueba gratuita de Magzter GOLD de 7 días para acceder a miles de historias premium seleccionadas y a más de 9,000 revistas y periódicos.
Ya eres suscriptor? Conectar
India, US extend 2% digital tax pact on e-commerce
India and the United States have decided to extend the agreement relating to 2 per cent equalisation levy, or digital tax, imposed by New Delhi on e-commerce platforms till June 30, the finance ministry said on Friday.
Brokerages turn bullish on telcos after tariff hike
Bharti Artel and Reliance Jio (RJio) announced a hike in tariffs across telecom plans with effect from July 3.
Emcure Pharma looks to raise ₹1,952 cr via IPO
Emcure Pharmaceuticals has set a price band of ₹960-1,008 per share for its initial public offering (IPO) that opens for subscription on July 3.
ICICI Prudential MF launches energy fund with eye on demand growth
ICICI Prudential Mutual Fund (MF) has announced the launch of Energy Opportunities Fund, a thematic scheme which will look to ride the energy growth demand wave and capture the emerging opportunities in the renewables space.
Geopolitics biggest risk to markets: Chris Wood
Geopolitics, particularly, the growing risk of escalation in the Russia-Ukraine conflict, remains by far the biggest risk the markets, wrote Christopher Wood (pictured), global head of equity strategy at Jefferies in his weekly note to investors, GREED & fear.
Indices snap winning streak
Equity benchmark Sensex on Friday fell for the first time in seven days, while the Nifty 50 index notched up its first loss in five days.
Navigating the hype-reality divide
It has been an education watching the T20 World Cup and the Euro on my mobile.
Attracting Netravalkars
EYE CULTURE VISHAL MENON The average Indian male loathes Saurabh Netravalkar.
A new paradigm for creating jobs
It would be prudent to take up a few sectors initially, get the policy instruments right, and put in the critical mass of resources to achieve a self-sustaining inflection point
Three elections, three mistakes
Joe Biden had a disastrous evening on the debate stage on Thursday.